Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.
Segalés L, Juanpere N, Gallarín N, Lorenzo M, López D, Perera-Bel J, Rodriguez-Vida A, Fumadó L, Cecchini L, Bellmunt J, Lloreta-Trull J, Hernández-Llodrà S. Segalés L, et al. Virchows Arch. 2024 Aug;485(2):281-290. doi: 10.1007/s00428-023-03699-z. Epub 2023 Nov 28. Virchows Arch. 2024. PMID: 38017230 Free PMC article.
New treatment options for metastatic renal cell carcinoma.
Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH. Rodriguez-Vida A, et al. ESMO Open. 2017 May 9;2(2):e000185. doi: 10.1136/esmoopen-2017-000185. eCollection 2017. ESMO Open. 2017. PMID: 28761748 Free PMC article. Review.
Avelumab for the treatment of urothelial cancer.
Rodriguez-Vida A, Bellmunt J. Rodriguez-Vida A, et al. Expert Rev Anticancer Ther. 2018 May;18(5):421-429. doi: 10.1080/14737140.2018.1448271. Epub 2018 Mar 14. Expert Rev Anticancer Ther. 2018. PMID: 29540084 Review.
The Cancer Genome Atlas Project in Bladder Cancer.
Rodriguez-Vida A, Lerner SP, Bellmunt J. Rodriguez-Vida A, et al. Cancer Treat Res. 2018;175:259-271. doi: 10.1007/978-3-319-93339-9_12. Cancer Treat Res. 2018. PMID: 30168126
Treatment of Metastatic Urothelial Cancer in 2018.
Bellmunt J, Rodriguez-Vida A. Bellmunt J, et al. JAMA Oncol. 2019 Jun 1;5(6):904-905. doi: 10.1001/jamaoncol.2019.0182. JAMA Oncol. 2019. PMID: 30973581 No abstract available.
Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.
Hernández-Prat A, Rodriguez-Vida A, Juanpere-Rodero N, Arpi O, Menéndez S, Soria-Jiménez L, Martínez A, Iarchouk N, Rojo F, Albanell J, Brake R, Rovira A, Bellmunt J. Hernández-Prat A, et al. Mol Cancer Res. 2019 Sep;17(9):1931-1944. doi: 10.1158/1541-7786.MCR-18-0923. Epub 2019 Jun 3. Mol Cancer Res. 2019. PMID: 31160383 Free article.
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
Bellmunt J, Kim J, Reardon B, Perera-Bel J, Orsola A, Rodriguez-Vida A, Wankowicz SA, Bowden M, Barletta JA, Morote J, de Torres I, Juanpere N, Lloreta-Trull J, Hernandez S, Mouw KW, Taplin ME, Cejas P, Long HW, Van Allen EM, Getz G, Kwiatkowski DJ. Bellmunt J, et al. Cancer Res. 2020 Oct 15;80(20):4476-4486. doi: 10.1158/0008-5472.CAN-20-0977. Epub 2020 Aug 31. Cancer Res. 2020. PMID: 32868381 Free PMC article.
82 results